Effects of moxonidine on corticocerebral blood flow under normal and ischemic conditions in conscious rabbits.
Hypertension associated with excessive liberation of circulating and tissue catecholamines is an independent risk factor for further cardiovascular complications and an important predictor of stroke. Moxonidine is a centrally acting anti-hypertensive drug with potent action on I1-imidazoline receptors. It inhibits catecholamine release and is therefore expected to exert an antiadrenergic effect at various levels in the regulation of the cardiovascular system. The aim of this study was to investigate the effect of moxonidine (0.025-0.1 mg/kg, i.v.) on the normal and unilateral carotid occlusion-induced impaired corticocerebral blood flow (cCBF) determined by hydrogen polarography, on mean arterial blood pressure (MABP) and heart rate (HR) in conscious rabbits. Moxonidine produced a reduction of MABP and HR. On the other hand, after administration of the drug, a significant increase in the normal and impaired cCBF was observed. Because the improvement in cCBF was conspicuous in both normal and ischemic conditions, moxonidine might be beneficial not only in the treatment of hypertension but also in the management of cerebral ischemia.
Csete
K
K
Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical University, Hungarian Academy of Sciences, Szeged. csete@phcol.szote.u-szeged.hu
Papp
J G
JG
D000704:Analysis of Variance; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002540:Cerebral Cortex / Q000098:blood supply; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D007093:Imidazoles / Q000494:pharmacology*; D007275:Injections, Intravenous; D007511:Ischemia / Q000503:physiopathology; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011048:Polarography; D011817:Rabbits
D007093:Imidazoles; D010975:Platelet Aggregation Inhibitors; C043482:moxonidine